Sugi Predict

Sugi Predict / Compounds / SCHEMBL10279976

SCHEMBL10279976

SCHEMBL10279976

CC(=O)CCCC(N)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSR P00390 2/20 0.56
▸ NOS2 P35228 6/20 0.55
▸ NOS1 P29475 5/20 0.55
▸ NOS3 P29474 3/20 0.55
▸ KMT2A Q03164 2/20 0.55
▸ CYP2C19 P33261 2/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ CYP1A2 P05177 3/20 0.54
▸ GRM8 O00222 1/20 0.54
▸ GRM6 O15303 1/20 0.54
▸ GRIN2D O15399 1/20 0.54
▸ GRIN3B O60391 1/20 0.54
▸ GRIK1 P39086 1/20 0.54
▸ GRM5 P41594 1/20 0.54
▸ GRIA1 P42261 1/20 0.54
▸ GRIA2 P42262 1/20 0.54
▸ GRIA3 P42263 1/20 0.54
▸ SLC1A3 P43003 1/20 0.54
▸ SLC1A2 P43004 1/20 0.54
▸ SLC1A1 P43005 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26747924 1.00 GSR (0.56) GSRNOS2NOS1NOS3KMT2A
SCHEMBL12516455 0.93 GSR (0.59) GSRNOS2NOS1NOS3KMT2A
SCHEMBL18834045 0.91 NOS2 (0.58) GSRNOS2NOS1NOS3KMT2A
SCHEMBL5126786 0.91 NOS2 (0.58) GSRNOS2NOS1NOS3KMT2A
SCHEMBL21896043 0.91 NOS2 (0.58) GSRNOS2NOS1NOS3KMT2A
SCHEMBL25537060 0.91 NOS2 (0.58) GSRNOS2NOS1NOS3KMT2A
SCHEMBL12273370 0.91 NOS2 (0.58) GSRNOS2NOS1NOS3KMT2A
SCHEMBL12634960 0.91 NOS2 (0.58) GSRNOS2NOS1NOS3KMT2A
SCHEMBL1330943 0.86 GSR (0.65) GSRNOS2NOS1NOS3KMT2A
SCHEMBL3867126 0.86 GSR (0.65) GSRNOS2NOS1NOS3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037405-B2 Anti-CD70 antibody drug conjugates AMBRX, INC. 2024-07-16 — — US disclosed
EP-3126375-B1 MACROCYCLIC PEPTIDOMIMETICS FOR ALPHA-HELIX MIMICRY UNIV ROCHESTER (US) 2023-12-13 — — EP disclosed
US-20230348547-A1 MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES AMBRX INC (US) 2023-11-02 — — US disclosed
US-11786578-B2 Modified relaxin polypeptides and their uses AMBRX, INC. (US) 2023-10-17 — — US disclosed
US-20230302150-A1 ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF AMBRX, INC. (US) 2023-09-28 — — US disclosed
US-20230295320-A1 Anti-CD70 Antibody Drug Conjugates AMBRX, INC. (US) 2023-09-21 — — US disclosed
US-20230226152-A1 INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF AMBRX, INC. 2023-07-20 — — US disclosed
EP-3225248-B1 MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES AMBRX INC (US) 2023-06-07 — — EP disclosed
US-20230158179-A1 RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF RAYZEBIO, INC. 2023-05-25 — — US disclosed
US-20230158179-A1 RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF RAYZEBIO, INC. 2023-05-25 — — US disclosed
WO-2012024452-A2 MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES AMBRX, INC. (US) 2012-02-23 — — WO disclosed
EP-2399893-A2 Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides Ambrx, Inc. (US) 2011-12-28 — — EP disclosed
US-20110294161-A1 Modified Human Growth Hormone AMBRX, INC. (US) 2011-12-01 — — US disclosed
WO-2011087810-A1 MODIFIED PORCINE SOMATOTROPIN POLYPEPTIDES AND THEIR USES AMBRX, INC. (US) 2011-07-21 — — WO disclosed
WO-2011079293-A1 TUMOR NECROSIS FACTOR-RELATED APOPTOSIS INDUCING LIGAND POLYPEPTIDES AND THEIR USES AMBRX, INC (US) 2011-06-30 — — WO disclosed
EP-2284191-A2 Process for the preparation of hGH Ambrx, Inc. (US) 2011-02-16 — — EP disclosed
WO-2010011735-A2 MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES AMBRX, INC. (US) 2010-01-28 — — WO disclosed
WO-2010006214-A1 FGF-21 NEUTRALIZING ANTIBODIES AND THEIR USES AMBRX, INC. (US) 2010-01-14 — — WO disclosed
WO-2009117622-A2 MODIFIED FGF-23 POLYPEPTIDES AND THEIR USES AMBRX, INC. (US) 2009-09-24 — — WO disclosed
WO-2006069220-A9 MODIFIED HUMAN GROWTH HORMONE AMBRX INC (US) 2007-08-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226152-A1 INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF IL2, IL2RA, TAP2 GSR 3523/4885NOS2 1049/4885NOS1 4161/4885
US-12037405-B2 Anti-CD70 antibody drug conjugates CD74, CD63, CD47 GSR 4873/4885NOS2 1667/4885NOS1 2210/4885
US-20230302150-A1 ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF TLR3, TLR1, TLR9 GSR 4178/4885NOS2 4241/4885NOS1 4297/4885
US-20230348547-A1 MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES CSF3R, GMFG, HDGF GSR 2625/4885NOS2 2298/4885NOS1 3226/4885
US-20230158179-A1 RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF PAICS, LNPEP, DNPEP GSR 1986/4885NOS2 4269/4885NOS1 4365/4885
US-20230295320-A1 Anti-CD70 Antibody Drug Conjugates CD63, CD74, CD99 GSR 4870/4885NOS2 2216/4885NOS1 2705/4885
US-11786578-B2 Modified relaxin polypeptides and their uses RXFP1, RXFP2, RXFP3 GSR 3276/4885NOS2 396/4885NOS1 624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.